Description
Anti-STOP-1 Antibody, Non-Fucosylated (BioBet-1651ZP) is a human monoclonal IgG antibody against STOP-1. This product is an ADCC enhanced antibody produced by our Afuco™ platform.
Antibody Indication
Cancer; Cardiovascular
Classification
Therapeutic antibody; biobetter
Cooperation Seeking
Creative Biolabs is interested in collaborating with potential partners (include but not limit to major pharma or biotech firms) to further co-develop ADCC-enhanced STOP-1 antibody. For commercial partners interested in our ADCC-enhanced therapeutic antibodies, Creative Biolabs welcomes collaboration. Here are two ways for your choice, and please contact us for more details.
1) Collaborate with us and co-develop the programs from discovery phase to IND enabling. Costs will be shared.
2) Become a licensed candidate of our programs.
Looking forward to cooperating with you in the near future.
Official Name
STOP-1
Full Name
STOP-1
Background
The cell which overexpresses a STOP-1 polypeptide is a cancer cell, e.g., a breast, ovarian, stomach, endometrial, salivary gland, lung, kidney, colon, thyroid, pancreatic or bladder cell, as compared to a normal cell of the same tissue type.
Alternative Names
STOP-1
Cellular Localization
Nucleus
Biologic Classification
Protein Based Therapies
Monoclonal antibody (mAb)
Antibody Isotype
IgG
Antibody Clone
BioBet-1651ZP
Description
The novel antibody bingding to the STOP-1 polypeptide are useful for the diagnosis and treatment of disorders involving angiogenesis and vasculogenesis (e.g., cardiovascular as well as oncological disorders).
Antibody Indication
Cancer; Cardiovascular
